Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)

NCT03184558 is registered in ClinicalTrials.gov with BerGenBio ASA as lead sponsor.

NCT NCT03184558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)
Lead sponsor
BerGenBio ASA
Phase
Phase 2
Overall status
Terminated
Start date
July 26, 2017
Completion date
August 20, 2018
Enrollment
29 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory breast cancer stage iv, triple negative breast cancer